AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22498212 — intervention group
Group type: EXPERIMENTAL
Intervention: Gleason 8 or greater
Number of subjects: 204
Study 22498212 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate/severe comorbidity
Number of subjects: 204
Study 22498212 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher prostate specific antigen nadir
Number of subjects: 204
Study 22498212 — intervention group
Group type: EXPERIMENTAL
Intervention: Older age
Number of subjects: 204
Study 20012532 — intervention group
Group type: EXPERIMENTAL
Intervention: Force task (constant force against a rigid restraint)
Number of subjects: 20
Study 20012532 — intervention group
Group type: EXPERIMENTAL
Intervention: Position task (maintain a constant elbow angle while supporting an inertial load)
Number of subjects: 20
Study 18554075 — intervention group
Group type: EXPERIMENTAL
Intervention: Common/unique presentation approach
Number of subjects: 303
Study 18554075 — intervention group
Group type: EXPERIMENTAL
Intervention: Providing an overarching framework
Number of subjects: 303
Study 18554075 — intervention group
Group type: EXPERIMENTAL
Intervention: Less numerate consumers
Number of subjects: 303
Study 15781825 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial ultrasound (sonothrombolysis) for 1 hour
Number of subjects: 15
Study 15781825 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 15
Study 11803183 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel (initial 300-mg loading dose, followed by 75-mg daily dose)
Number of subjects: 12500
Study 11803183 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12500
Study 10788023 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse Practitioner
Number of subjects: 450
Study 7621454 — intervention group
Group type: EXPERIMENTAL
Intervention: Radical prostatectomy
Number of subjects: 0
Study 7621454 — intervention group
Group type: COMPARATOR
Intervention: External radiation therapy
Number of subjects: 0
Study 7621454 — intervention group
Group type: COMPARATOR
Intervention: Deferred treatment
Number of subjects: 0
Study 2199290 — intervention group
Group type: EXPERIMENTAL
Intervention: Colchicine (1 mg orally every morning)
Number of subjects: 72
Study 2199290 — intervention group
Group type: COMPARATOR
Intervention: Placebo (identical to colchicine)
Number of subjects: 72
Study 2199290 — intervention group
Group type: EXPERIMENTAL
Intervention: Colchicine
Number of subjects: 72
Study 2199290 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study 400861 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg NA‐872 daily for 5 days
Number of subjects: 0
Study 400861 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg NA‐872 daily for 5 days
Number of subjects: 0
Study 7119300 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone liquid
Number of subjects: 12
Study 7119300 — intervention group
Group type: COMPARATOR
Intervention: Prednisone tablet
Number of subjects: 12
Study 7119300 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone sodium phosphate
Number of subjects: 12
Study 29412001 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 minutes of feedback training inspired by Implicit Person Theory (IPT)
Number of subjects: 0
Study 29412001 — intervention group
Group type: COMPARATOR
Intervention: Control group (untrained attending physicians)
Number of subjects: 0
Study 30446595 — intervention group
Group type: EXPERIMENTAL
Intervention: Lasmiditan 200 mg
Number of subjects: 1856
Study 30446595 — intervention group
Group type: EXPERIMENTAL
Intervention: Lasmiditan 100 mg
Number of subjects: 1856
Study 30446595 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1856
Study 27073123 — intervention group
Group type: EXPERIMENTAL
Intervention: Same-day PPM implantation (Group A)
Number of subjects: 168
Study 27073123 — intervention group
Group type: COMPARATOR
Intervention: Delayed PPM implantation (Group B)
Number of subjects: 168
Study 25137188 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine treatment over 12 weeks (8 sessions)
Number of subjects: 234
Study 22512287 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedicine system with automated reminders
Number of subjects: 80
Study 22512287 — intervention group
Group type: COMPARATOR
Intervention: Control group (paper logbooks)
Number of subjects: 80
Study 22512287 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedicine system
Number of subjects: 80
Study 22512287 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 80
Study 18691791 — intervention group
Group type: EXPERIMENTAL
Intervention: Point-of-care testing
Number of subjects: 2000
Study 18691791 — intervention group
Group type: COMPARATOR
Intervention: Central laboratory markers only (laboratory arm)
Number of subjects: 2000
Study 18056489 — intervention group
Group type: EXPERIMENTAL
Intervention: Simple decompression
Number of subjects: 361
Study 18056489 — intervention group
Group type: COMPARATOR
Intervention: Anterior transposition of the ulnar nerve
Number of subjects: 361
Study 15230343 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg disodium clodronate with 1% lidocaine
Number of subjects: 30
Study 15230343 — intervention group
Group type: COMPARATOR
Intervention: Clody (same formulation without local anaesthetic)
Number of subjects: 30
Study 15230343 — intervention group
Group type: COMPARATOR
Intervention: Clasteon (marketed formulation containing 1% benzyl alcohol)
Number of subjects: 30
Study 12131187 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-specific CD8 T cells
Number of subjects: 0
Study 12131187 — intervention group
Group type: EXPERIMENTAL
Intervention: CMV-specific CD8 T cells
Number of subjects: 0
Study 9823912 — intervention group
Group type: EXPERIMENTAL
Intervention: [18F]fluorodeoxyglucose (FDG) PET scan
Number of subjects: 50
Study 9823912 — intervention group
Group type: COMPARATOR
Intervention: Computed Tomography (CT)
Number of subjects: 50
Study 7911813 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabergoline (0.5 mg twice weekly)
Number of subjects: 12
Study 7911813 — intervention group
Group type: COMPARATOR
Intervention: Quinagolide (75 micrograms once daily)
Number of subjects: 12
Study 2593891 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietitian advice (n = 31)
Number of subjects: 59
Study 2593891 — intervention group
Group type: COMPARATOR
Intervention: Diet fact sheet (n = 28)
Number of subjects: 59
Study 183605 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG immunoprophylaxis
Number of subjects: 38
Study 183605 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 30839438 — intervention group
Group type: EXPERIMENTAL
Intervention: Vessel loop drainage
Number of subjects: 81
Study 30839438 — intervention group
Group type: COMPARATOR
Intervention: Standard incision and drainage (I&D)
Number of subjects: 81
Study 30986791 — intervention group
Group type: EXPERIMENTAL
Intervention: RotaTeq vaccine
Number of subjects: 19133
Study 30986791 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19133
Study 28123149 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual antiplatelet therapy (DAPT)
Number of subjects: 144
Study 28123149 — intervention group
Group type: COMPARATOR
Intervention: Aspirin alone
Number of subjects: 144
Study 28123149 — intervention group
Group type: EXPERIMENTAL
Intervention: DAPT
Number of subjects: 144
Study 26688732 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin DPI 32.5 mg
Number of subjects: 286
Study 26688732 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin DPI 48.75 mg
Number of subjects: 286
Study 26688732 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin DPI (pooled data)
Number of subjects: 286
Study 26688732 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin DPI
Number of subjects: 286
Study 26688732 — intervention group
Group type: COMPARATOR
Intervention: Placebo 32.5 mg
Number of subjects: 286
Study 26688732 — intervention group
Group type: COMPARATOR
Intervention: Placebo 48.75 mg
Number of subjects: 286
Study 23576486 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetuximab in combination with cisplatin or carboplatin and 5-fluorouracil
Number of subjects: 442
Study 21041278 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin therapy (40 mg/day) combined with methotrexate (MTX; 0.2 mg/kg/week) and prednisone (10 mg/day)
Number of subjects: 30
Study 21041278 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate (MTX; 0.2 mg/kg/week) plus prednisone (10 mg/day)
Number of subjects: 30
Study 21041278 — intervention group
Group type: COMPARATOR
Intervention: Healthy individuals (control group)
Number of subjects: 30
Study 19124513 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise (150 minutes per week of moderate‐intensity)
Number of subjects: 75
Study 19124513 — intervention group
Group type: COMPARATOR
Intervention: Usual care (maintaining current physical activity level)
Number of subjects: 75
Study 17219217 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam XR (1 mg)
Number of subjects: 18
Study 17219217 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam IR (1 mg)
Number of subjects: 18
Study 17219217 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 15145877 — intervention group
Group type: EXPERIMENTAL
Intervention: Stent implantation
Number of subjects: 0
Study 15145877 — intervention group
Group type: COMPARATOR
Intervention: PTCA (balloon angioplasty)
Number of subjects: 0
Study 11059965 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol added to low-dose inhaled corticosteroids (ICS)
Number of subjects: 0
Study 11059965 — intervention group
Group type: COMPARATOR
Intervention: Fluticasone propionate (FP)
Number of subjects: 0
Study 11059965 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 8872688 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam 0.5 mg/kg orally
Number of subjects: 72
Study 8872688 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study 1623899 — intervention group
Group type: EXPERIMENTAL
Intervention: Metamizole 3 x 1 g for 3 days
Number of subjects: 12
Study 1623899 — intervention group
Group type: COMPARATOR
Intervention: Furosemide 20 mg IV
Number of subjects: 12
Study 6367875 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 45
Study 6367875 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 6367875 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapist-aided exposure
Number of subjects: 45
Study 6367875 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation
Number of subjects: 45
Study 6367875 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-exposure homework
Number of subjects: 45
Study 6367875 — intervention group
Group type: EXPERIMENTAL
Intervention: Spontaneous panics
Number of subjects: 45
Study 30690511 — intervention group
Group type: EXPERIMENTAL
Intervention: EPS trajectory
Number of subjects: 9
Study 30690511 — intervention group
Group type: COMPARATOR
Intervention: S1AS trajectory
Number of subjects: 9
Study 29299776 — intervention group
Group type: EXPERIMENTAL
Intervention: Monetary reward for fast and accurate task performance
Number of subjects: 0
Study 29299776 — intervention group
Group type: COMPARATOR
Intervention: No monetary reward (control group)
Number of subjects: 0
Study 26650133 — intervention group
Group type: EXPERIMENTAL
Intervention: Milking of the cord 4 times
Number of subjects: 58
Study 26650133 — intervention group
Group type: COMPARATOR
Intervention: Delayed cord clamping
Number of subjects: 58
Study 26650133 — intervention group
Group type: EXPERIMENTAL
Intervention: Milking of the cord 4 times (girls)
Number of subjects: 58
Study 26650133 — intervention group
Group type: EXPERIMENTAL
Intervention: Milking of the cord 4 times (boys)
Number of subjects: 58
Study 25651293 — intervention group
Group type: EXPERIMENTAL
Intervention: Horizontal incision
Number of subjects: 63
Study 25651293 — intervention group
Group type: COMPARATOR
Intervention: Vertical incision
Number of subjects: 63
Study 24308310 — intervention group
Group type: EXPERIMENTAL
Intervention: Baduanjin training (1 hour per day, 5 days per week for 12 weeks)
Number of subjects: 222
Study 24308310 — intervention group
Group type: COMPARATOR
Intervention: Usual exercise control group
Number of subjects: 222
Study 20409311 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic training alone
Number of subjects: 160
Study 20409311 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training alone
Number of subjects: 160
Study 20409311 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of aerobic and resistance training
Number of subjects: 160
Study 20409311 — intervention group
Group type: COMPARATOR
Intervention: Attention-control (progressive stretching)
Number of subjects: 160
Study 20409311 — intervention group
Group type: EXPERIMENTAL
Intervention: All exercise training groups
Number of subjects: 160
Study 17984104 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramipril
Number of subjects: 46
Study 17984104 — intervention group
Group type: COMPARATOR
Intervention: Metoprolol
Number of subjects: 46
Study 17984104 — intervention group
Group type: EXPERIMENTAL
Intervention: Rigorous BP control
Number of subjects: 46
Study 17984104 — intervention group
Group type: COMPARATOR
Intervention: Standard BP control
Number of subjects: 46
Study 15710957 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy with pegylated interferon-alpha2b (1.5 microg/kg/week for 32 weeks) plus lamivudine (100 mg daily for 52 weeks)
Number of subjects: 100
Study 15710957 — intervention group
Group type: COMPARATOR
Intervention: Lamivudine monotherapy (100 mg daily for 52 weeks)
Number of subjects: 100
Study 15710957 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy
Number of subjects: 100
Study 15710957 — intervention group
Group type: COMPARATOR
Intervention: Lamivudine monotherapy
Number of subjects: 100
Study 12804927 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombolysis alone
Number of subjects: 250
Study 12804927 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombolysis plus abciximab
Number of subjects: 250
Study 12804927 — intervention group
Group type: EXPERIMENTAL
Intervention: Stenting plus abciximab
Number of subjects: 250
Study 12804927 — intervention group
Group type: EXPERIMENTAL
Intervention: High CRP group (CRP >12 mg/l)
Number of subjects: 250
Study 12804927 — intervention group
Group type: COMPARATOR
Intervention: Low CRP group (CRP ≤12 mg/l)
Number of subjects: 250
Study 11029125 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol drops (2.5 mg kg(‐1))
Number of subjects: 50
Study 11029125 — intervention group
Group type: COMPARATOR
Intervention: Paracetamol (acetaminophen) suppositories (15 mg kg(‐1))
Number of subjects: 50
Study 8711649 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled bronchodilators or steroids
Number of subjects: 783
Study 8711649 — intervention group
Group type: EXPERIMENTAL
Intervention: Diagnosis of asthma or chronic bronchitis
Number of subjects: 783
Study 8711649 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary function testing
Number of subjects: 783
Study 8711649 — intervention group
Group type: EXPERIMENTAL
Intervention: Respiratory symptoms
Number of subjects: 783
Study 8711649 — intervention group
Group type: EXPERIMENTAL
Intervention: Potential improvement on treatment
Number of subjects: 783
Study 1355345 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetirizine 10 mg/day for 15 days
Number of subjects: 34
Study 1355345 — intervention group
Group type: COMPARATOR
Intervention: Astemizole 10 mg/day for 15 days
Number of subjects: 34
Study 6432869 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous nitroglycerin (NG) for 48 hours
Number of subjects: 140
Study 6432869 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 140
Study 31731467 — intervention group
Group type: EXPERIMENTAL
Intervention: Coffee ingestion (0.09 g·kg‐1 coffee providing 3 mg·kg‐1 of caffeine)
Number of subjects: 38
Study 31731467 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 38
Study 31731467 — intervention group
Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 38
Study 29949041 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin 25 mg/linagliptin 5 mg
Number of subjects: 1363
Study 29949041 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin 10 mg/linagliptin 5 mg
Number of subjects: 1363
Study 29949041 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin 25 mg
Number of subjects: 1363
Study 29949041 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin 10 mg
Number of subjects: 1363
Study 29949041 — intervention group
Group type: EXPERIMENTAL
Intervention: Linagliptin 5 mg
Number of subjects: 1363
Study 29949041 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin/linagliptin or empagliflozin
Number of subjects: 1363
Study 29949041 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatment groups
Number of subjects: 1363
Study 27655505 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical fragmentation combined with rt‐PA artery thrombolysis
Number of subjects: 132
Study 27655505 — intervention group
Group type: COMPARATOR
Intervention: rt‐PA artery thrombolysis
Number of subjects: 132
Study 24830742 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral external ventricular drains (EVD)
Number of subjects: 47
Study 24830742 — intervention group
Group type: COMPARATOR
Intervention: Single external ventricular drain (EVD)
Number of subjects: 47
Study 22369221 — intervention group
Group type: EXPERIMENTAL
Intervention: PTSD severity
Number of subjects: 29
Study 22369221 — intervention group
Group type: EXPERIMENTAL
Intervention: Startle and anger/irritability symptoms of PTSD
Number of subjects: 29
Study 22369221 — intervention group
Group type: EXPERIMENTAL
Intervention: Nightmares, emotional numbing, and hypervigilance symptoms of PTSD
Number of subjects: 29
Study 22369221 — intervention group
Group type: EXPERIMENTAL
Intervention: Anger/irritability symptom of PTSD
Number of subjects: 29
Study 20214894 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin therapy for 3 months
Number of subjects: 20
Study 20214894 — intervention group
Group type: COMPARATOR
Intervention: Control (no metformin therapy)
Number of subjects: 20
Study 18758125 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 2.5 mg/dL
Number of subjects: 38
Study 18758125 — intervention group
Group type: COMPARATOR
Intervention: Non-rosuvastatin therapy
Number of subjects: 38
Study 15641102 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab plus methotrexate (MTX)
Number of subjects: 20
Study 15641102 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus methotrexate (MTX)
Number of subjects: 20
Study 12621384 — intervention group
Group type: EXPERIMENTAL
Intervention: Itraconazole 200 mg orally twice a day for 2 days
Number of subjects: 12
Study 12621384 — intervention group
Group type: EXPERIMENTAL
Intervention: Grapefruit juice 200 mL 3 times a day for 2 days
Number of subjects: 12
Study 12621384 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 10321418 — intervention group
Group type: COMPARATOR
Intervention: 8 mg conventional ondansetron tablet (OT) taken twice daily
Number of subjects: 427
Study 10321418 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 mg orally disintegrating ondansetron tablet (ODT) taken twice daily
Number of subjects: 427
Study 8317343 — intervention group
Group type: EXPERIMENTAL
Intervention: Microdialysis method to collect dialysate samples from inflamed tissue
Number of subjects: 0
Study 2883698 — intervention group
Group type: EXPERIMENTAL
Intervention: midazolam 15 mg orally followed by intravenous saline
Number of subjects: 40
Study 2883698 — intervention group
Group type: COMPARATOR
Intervention: oral placebo followed by intravenous diazepam 10 mg (Diazemuls)
Number of subjects: 40
Study 27768384 — intervention group
Group type: EXPERIMENTAL
Intervention: Family group cognitive behavioral intervention (FGCB)
Number of subjects: 242
Study 27768384 — intervention group
Group type: COMPARATOR
Intervention: Written information (WI) control
Number of subjects: 242
Study 26855120 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 highly unsaturated fatty acids (n-3 HUFAs) supplementation in the form of all natural fruit juice beverages
Number of subjects: 0
Study 26855120 — intervention group
Group type: COMPARATOR
Intervention: Placebo (all natural fruit juice beverages)
Number of subjects: 0
Study 26855120 — intervention group
Group type: EXPERIMENTAL
Intervention: n-3 HUFAs
Number of subjects: 0
Study 25186034 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib 5 mg twice daily
Number of subjects: 399
Study 25186034 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib 10 mg twice daily
Number of subjects: 399
Study 25186034 — intervention group
Group type: COMPARATOR
Intervention: Placebo advanced to tofacitinib 5 mg twice daily
Number of subjects: 399
Study 25186034 — intervention group
Group type: COMPARATOR
Intervention: Placebo advanced to tofacitinib 10 mg twice daily
Number of subjects: 399
Study 23850450 — intervention group
Group type: EXPERIMENTAL
Intervention: AC-T (doxorubicin and cyclophosphamide followed by docetaxel)
Number of subjects: 201
Study 23850450 — intervention group
Group type: COMPARATOR
Intervention: TAC (docetaxel, doxorubicin, and cyclophosphamide)
Number of subjects: 201
Study 23850450 — intervention group
Group type: EXPERIMENTAL
Intervention: AC-T without primary G-CSF prophylaxis
Number of subjects: 201
Study 23850450 — intervention group
Group type: COMPARATOR
Intervention: TAC with primary G-CSF prophylaxis
Number of subjects: 201
Study 21670542 — intervention group
Group type: EXPERIMENTAL
Intervention: Apixaban 2.5 mg b.i.d.
Number of subjects: 222
Study 21670542 — intervention group
Group type: EXPERIMENTAL
Intervention: Apixaban 5 mg b.i.d.
Number of subjects: 222
Study 21670542 — intervention group
Group type: COMPARATOR
Intervention: Warfarin (target INR 2.0-3.0; 2.0-2.6 if age ≥ 70 years)
Number of subjects: 222
Study 19567532 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg DHEA daily for 2 years (women)
Number of subjects: 122
Study 19567532 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 mg DHEA daily for 2 years (men)
Number of subjects: 122
Study 19567532 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg testosterone (patch) daily for 2 years (men)
Number of subjects: 122
Study 19567532 — intervention group
Group type: COMPARATOR
Intervention: Placebo daily for 2 years (women and men)
Number of subjects: 122
Study 16123739 — intervention group
Group type: EXPERIMENTAL
Intervention: DMT (low dose)
Number of subjects: 15